BOT
vs
S
S&P/ASX 300
BOT
Over the past 12 months, BOT has underperformed S&P/ASX 300, delivering a return of -70% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
BOT vs S&P/ASX 300
Performance Gap
BOT vs S&P/ASX 300
Performance By Year
BOT vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Botanix Pharmaceuticals Ltd
Glance View
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.